Table 5.
The clinical characteristics of pyogenic liver abscess with DM between poor-control of glycaemia group and good-control of glycaemia group
| Variables | good-control of glycaemia (n = 23) | poor-control of glycaemia (n = 38) | p value |
|---|---|---|---|
| Age (years) | 57 (22–84) | 58 (23–80) | 0.951 |
| Gender (male) | 15 (65.22%) | 24 (63.16%) | 0.871 |
| Diabetes duration (years) | 5.4 (0.4–27) | 5.5 (0.2–30) | 0.952 |
| Underlying condition | |||
| Smoking | 8 (34.78%) | 8 (21.05%) | 0.237 |
| Drinking | 5 (21.74%) | 5 (13.16%) | 0.603 |
| Hypertension | 6 (27.27%) | 6 (15.79%) | 0.461 |
| Diabetic vascular diseases | |||
| Micro-angiopathy | 2 (8.70%) | 8 (21.05%) | 0.294 |
| Macro-angiopathy | 2 (8.70%) | 3 (7.89%) | 1.000 |
| Laboratory tests | |||
| WBC > 10 × 109/L | 7 (30.43%) | 16 (42.11%) | 0.362 |
| WBC < 3.5 × 109/L | 2 (8.70%) | 1 (2.63%) | 0.652 |
| ALT > 40 U/L | 12 (52.17%) | 13 (34.21%) | 0.167 |
| AST > 40 U/L | 7 (30.43%) | 8 (21.05%) | 0.410 |
| ALB < 35 g/L | 16 (69.57%) | 29 (76.32%) | 0.561 |
| TBIL > 17 μmol/L | 14 (60.87%) | 17 (44.74%) | 0.222 |
| PT > 17 s | 4 (17.39%) | 2 (5.26%) | 0.272 |
| APTT > 45 s | 3 (13.04%) | 4 (10.53%) | 1.000 |
| BUN > 7.2 mmol/L | 2 (8.70%) | 5 (13.51%) | 0.697 |
| Cr > 97 μmol/L | 2 (8.70%) | 5 (13.51%) | 0.697 |
| Abscess number | |||
| Solitary abscess | 18 (78.26%) | 29 (76.32%) | 0.861 |
| Multiple abscess | 5 (21.74%) | 9 (23.68%) | |
| Maximal diameter of abscess | |||
| ≤ 5 cm | 11 (47.83%) | 13 (34.21%) | 0.178 |
| 5~10 cm | 11 (47.83%) | 23 (60.53%) | |
| > 10 cm | 1 (4.35%) | 2 (5.26%) | |
| Abscess site | |||
| Left lobe | 4 (17.39%) | 2 (5.36%) | 0.220 |
| Right lobe | 13 (56.52%) | 30 (78.95%) | |
| Both left and right | 5 (21.74%) | 4 (10.53%) | |
| Other sites | 1 (4.35%) | 2 (5.26%) | |
| Medicine use | |||
| Steroid hormone | 10 (43.48%) | 11 (28.95%) | 0.247 |
| Hepatoprotective drugs | 14 (60.87%) | 22 (57.89%) | 0.819 |
| Immune response enhancer | 10 (43.48%) | 14 (36.84%) | 0.607 |
| Klebsiella pneumonia infection | 4 (17.39%) | 11 (28.95%) | 0.310 |
| Escherichia coli infection | 2 (8.70%) | 3 (7.89%) | 1.000 |
| Treatments | |||
| Percutaneous drainage | 6 (26.09%) | 23 (60.53%) | 0.027 |
| Surgical drainage | 3 (13.04%) | 4 (10.53%) | |
| Conservative treatment | 14 (60.87%) | 11 (28.95%) | |
| Antibiotic use | |||
| Combined | 10 (43.48%) | 27 (71.05%) | 0.033 |
| Single | 13 (56.52%) | 11 (28.95%) | |
| Outcomes | |||
| Cured | 16 (69.57%) | 29 (76.34%) | 0.565 |
| Improved | 7 (30.43%) | 9 (23.68%) | |
| Death | 0 (0%) | 0 (0%) | |
| Hospital stay (days) | 15 (3–40) | 15 (3–28) | 0.986 |
| Total Hospitalization expenses (× 1000 dollars) | 2.21 (3.15–7.79) | 6.04 (0.61–27.16) | 0.056 |
| Reoccurrence in three months | 1 (4.35%) | 5 (13.16%) | 0.395 |
| Survival (yes/no) in six months | 17 (73.91%) | 33 (86.84%) | 0.353 |
WBC white blood cell, ALT alanine transaminase, AST aspartate transaminase, ALB albumin, TBIL total bilirubin, PT prothrombin time, APTT activated partial thromboplastin time, BUN blood urea nitrogen, Cr creatinine